Wells Fargo analyst Brandon Couillard has maintained their bullish stance on TMO stock, giving a Buy rating on July 28.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brandon Couillard has given his Buy rating due to a combination of factors that highlight Thermo Fisher’s strong performance and market positioning. The company’s recent 10-Q filing revealed significant growth in key segments such as Pharma Services, Bioproduction, and the Research/Safety Channel, indicating robust momentum in these areas.
Furthermore, Thermo Fisher appears to be gaining market share, particularly in the Research/Safety Market Channel, where it outperformed competitors like AVTR. Despite some weaknesses in Analytical Instruments, the overall growth in critical segments like BioProduction, which outpaced peers, supports a positive outlook for the company’s stock.
According to TipRanks, Couillard is a 5-star analyst with an average return of 13.8% and a 58.71% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Thermo Fisher, Exact Sciences, and Maravai Lifesciences Holdings.
In another report released on July 28, Scotiabank also maintained a Buy rating on the stock with a $590.00 price target.